World Health Organization agrees legally binding pandemic treaty

The World Health Organization (WHO) members agreed to the text of the legal binding treaty designed to better deal with future infectious diseases.

This agreement is intended to avoid disorder and competition for resources in Covid-19.

The main factors include sharing data on new diseases quickly, and scientists and pharmaceutical companies make it possible to work faster to develop treatment and vaccines.

For the first time, the WHO itself will have an overview of a global supply chain for masks, medical gowns and other personal protection equipment (PPE).

Tedros Adhanom Ghebreyesus portrayed the deal as “an important milestone in our joint trip to a safer world.”

“[Member states] In addition, multilateralism is alive and well alive, and in our divided world, the state can still work together to find a common basis and to share a shared response to shared threats. “

At the beginning of Wednesday, the legal binding agreement came out after three years of conversation between member states.

The second in the WHO’s 75 -year history is the tobacco control trading in 2003 that reached this type of international convention.

Members must be officially adopted when they meet at the World Health Meeting next month.

After President Donald Trump announced his decision to withdraw from a global health agency, US negotiators did not participate in the final discussion, and when they left in 2026, the United States would not be arrested.

Under the agreement, the state should be able to use fashionable drugs worldwide around the world.

Participating manufacturers must assign 20%of vaccines, treatments and diagnosis to WHO. At least 10%must be donated with the rest of the parts provided at a low price.

The nations also approved to relocate health technology to a poor country as long as they had a “mutual agreement.”

In addition, more local vaccines and pharmaceuticals can be produced during the epidemic period. But the provisions were very controversial.

Developing countries are still angry at the way that wealthy countries buy and reserve vaccines during the COVID-19 period.

At the heart of the contract is the proposed pathogenic access and benefit sharing system (PABS), and data exchange between pharmaceutical companies is faster.

This allows the company to work faster in the future.